|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004114,
umls-concept:C0005516,
umls-concept:C0013216,
umls-concept:C0030705,
umls-concept:C0032790,
umls-concept:C0076080,
umls-concept:C0123931,
umls-concept:C0205195,
umls-concept:C0220825,
umls-concept:C0282460,
umls-concept:C0851346
|
|
pubmed:issue |
6C
|
|
pubmed:dateCreated |
2007-1-11
|
|
pubmed:abstractText |
Clinical studies have shown that temozolomide (TMZ) and irinotecan demonstrate activity in high grade astrocytic tumors (HGAT). However, the optimal schedule of administration is unknown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/Ki-67 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN Phosphohydrolase,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor C,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan,
http://linkedlifedata.com/resource/pubmed/chemical/temozolomide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
pubmed-author:BobosMattheosM,
pubmed-author:FountzilasGeorgeG,
pubmed-author:IgnatiadisMichailM,
pubmed-author:Kalogera-FountzilaAnnaA,
pubmed-author:KaravelisAntoniosA,
pubmed-author:KarinaMariaM,
pubmed-author:KarkavelasGeorgeG,
pubmed-author:KoukoulisGeorgeG,
pubmed-author:MisailidouDespinaD,
pubmed-author:PectasidesDimitriosD,
pubmed-author:PlataniotisGeorgeG,
pubmed-author:RazisEvangeliaE,
pubmed-author:SelviaridisPanagiotisP
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4675-86
|
|
pubmed:meshHeading |
pubmed-meshheading:17214326-Adult,
pubmed-meshheading:17214326-Aged,
pubmed-meshheading:17214326-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17214326-Astrocytoma,
pubmed-meshheading:17214326-Brain Neoplasms,
pubmed-meshheading:17214326-Camptothecin,
pubmed-meshheading:17214326-Combined Modality Therapy,
pubmed-meshheading:17214326-Cyclooxygenase 2,
pubmed-meshheading:17214326-Dacarbazine,
pubmed-meshheading:17214326-Feasibility Studies,
pubmed-meshheading:17214326-Female,
pubmed-meshheading:17214326-Glioblastoma,
pubmed-meshheading:17214326-Humans,
pubmed-meshheading:17214326-Ki-67 Antigen,
pubmed-meshheading:17214326-Male,
pubmed-meshheading:17214326-Middle Aged,
pubmed-meshheading:17214326-PTEN Phosphohydrolase,
pubmed-meshheading:17214326-Patient Compliance,
pubmed-meshheading:17214326-Postoperative Care,
pubmed-meshheading:17214326-Tumor Markers, Biological,
pubmed-meshheading:17214326-Vascular Endothelial Growth Factor C
|
|
pubmed:articleTitle |
Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.
|
|
pubmed:affiliation |
Department of Medical Oncology, Aristotle University of Thessaloniki, Thessaloniki, Greece. fountzil@med.auth.gr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
